TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06428409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Given by IV infusion every 2 weeks (Day 1 and Day 15 of every 4-week cycle)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Given by IV infusion every 2 weeks (Day 1 and Day 15 of every 4-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV) or levoleucovorin
Description: LV or levoleucovorin is administered by IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive care measures
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive care measures
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
Study: NCT06326450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset
Description: Augmented simulation of medical crisis scenarios
Study: NCT05605522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225]-FPI-2059
Description: \[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225]-FPI-2059
Description: \[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-2058
Description: \[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-2058
Description: \[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
Study: NCT06150560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 50mg administered orally once daily for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg Amlodipine administered orally once daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
Study: NCT05147558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg every 3 weeks, intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib (20mg once daily orally)
Study: NCT06468501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price reduction on healthier foods
Description: Price reduction (10%) on healthier foods based on the UK NPM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price increase to less healthy foods
Description: Price increase (10%) on less healthy foods based on the UK NPM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of price reduction on healthier foods and price increase on less healthy foods
Description: Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Existing price structure
Study: NCT05085977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
Study: NCT06481306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986470
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986470
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986470
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986470
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986470
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06060626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation using only Propofol.
Description: Patients in whom only propofol will be administered during sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation using combination of Propofol and Fentanyl.
Description: Patients in whom combination of propofol and fentanyl will be administered during sedation.
Study: NCT03902951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06245564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5%
Description: Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine + amitriptyline
Description: A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A vehicle cream will be applied in a 4x4 area in the forearm of each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: After the cream removal, itch will be induced using histamine in the first session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: After the cream removal, itch will be induced using cowhage in the second session
Study: NCT05383352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
Study: NCT04682288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Ocular Implant
Description: Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Study: NCT05383352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle
Study: NCT05271578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized Electronic Research Cigarette
Description: Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized Electronic Research Cigarette
Description: Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nicotine Research Cigarette
Description: Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nicotine Research Cigarette
Description: Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)
Study: NCT06462365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 infusion via central line.
Study: NCT06579989

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for cough
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for dysphagia
Description: Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound for dysphonia
Description: Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
Study: NCT06580938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07921585
Description: IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07921585
Description: IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07921585
Description: IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously
Study: NCT06106009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)
Study: NCT06167733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERTICA Active device
Description: VERTICA device with a therapeutic RF energy level

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VERTICA Sham device
Description: VERTICA device with a low, non-therapeutic RF energy level
Study: NCT05440422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anifrolumab
Description: This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
Study: NCT06106009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)
Study: NCT05830851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS and aerobic exercise
Description: Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real tDCS and aerobic exercise
Description: Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS and aerobic exercise
Description: Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS and aerobic exercise
Description: Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
Study: NCT06550596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axolotl DualGraft + SOC
Description: Participants will receive weekly applications of Axolotl DualGraft and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study: NCT06106009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)
Study: NCT05411237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: PLD 20 mg/m2 on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: PTX 100 mg/m2 on Day 1 of every 21-day cycle
Study: NCT04340596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803 (IL-15 Superagonist)
Description: Administered by subcutaneous (SQ) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803 (IL-15 Superagonist)
Description: Administered by subcutaneous (SQ) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Administered by intravenous (IV) infusion
Study: NCT05519228

Intervention type: DEVICE
Intervention: ToggleLoc 2.9 mm Soft Tissue System
Description: The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
Study: NCT06785636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pocenbrodib
Description: Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.
Study: NCT04813445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
Study: NCT06785636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pocenbrodib
Description: Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
Description: Pocenbrodib alone or in combination